**Policy Summary:**
The Technology Development Board (TDB), under the Department of Science and Technology, Government of India, is supporting Ms. Aodh Lifesciences Pvt. Ltd., Hyderabad, in developing an indigenous antibiotic nebulization suspension (AONEUM04) for pneumonia and antimicrobial resistance (AMR). This initiative aligns with the Atmanirbhar Bharat vision and aims to position India as a leader in affordable healthcare technologies. AONEUM04 offers a novel approach to antibiotic delivery through direct, localized nebulization, increasing drug concentration in the lungs while minimizing systemic side effects. The formulation combines sustained release, mucoadhesion, and biofilm disruption capabilities, enhancing efficacy and reducing antibiotic resistance. Having cleared preclinical trials, AONEUM04 will proceed to Phase III clinical trials. The technology is expected to improve treatment compliance and affordability, with potential for both Indian and global markets. TDB Secretary Sh. Rajesh Kumar Pathak emphasizes the project's significance in addressing pneumonia and AMR, while Aodh Lifesciences Pvt. Ltd. highlights its mission to provide accessible, effective, and safe treatments while combating global AMR. Release ID: 2165608
Key Entities Referenced
Viksit Bharat: A vision of the Prime Minister of India for a developed India.
Technology Development Board (TDB): A statutory body of the Department of Science and Technology, Government of India, that supports commercialization of indigenous technologies.
Department of Science and Technology: A department within the Government of India responsible for science and technology related matters.
Aodh Lifesciences Pvt. Ltd.: A startup company based in Hyderabad, Telangana, developing an indigenous antibiotic nebulization suspension for pneumonia.
Hyderabad, Telangana: Location of Aodh Lifesciences Pvt. Ltd.
AONEUM04: Indigenous Antibiotic Nebulization Suspension for Pneumonia being developed by Aodh Lifesciences Pvt. Ltd.
Antimicrobial Resistance (AMR): A condition when microorganisms become resistant to antimicrobial drugs, making infections harder to treat.
Rajesh Kumar Pathak: Secretary, Technology Development Board (TDB).
Ministry of Science & Technology
"Towards Viksit Bharat: TDB enables Startup to
Redefine Pneumonia Treatment"
“TDB-DST supports M/s Aodh Lifesciences Pvt. Ltd.
for Development of Indigenous Antibiotic
Nebulization Suspension for Pneumonia and
Antimicrobial Resistance”
Posted On: 11 SEP 2025 2:17PM by PIB Delhi
In line with the Prime Minister’s vision of Atmanirbhar Bharat and contributing to India’s aspiration of
becoming a global leader in affordable healthcare technologies, the Technology Development
Board (TDB), Department of Science and Technology, Government of India, has extended support
to M/s Aodh Lifesciences Pvt. Ltd., Hyderabad for development of Indigenous Antibiotic
Nebulization Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
The novel technology represents a paradigm shift in antibiotic delivery. Unlike conventional oral or
intravenous therapies, AONEUM-04 enables direct, localized delivery of Antibioticthrough
nebulization, ensuring higher drug concentration at the site of infection in the lungs while reducing
systemic side effects. Its unique formulation combines sustained release, strong mucoadhesion,
and biofilm disruption capabilities, thereby enhancing efficacy and reducing the likelihood of
antibiotic resistance. This makes it particularly relevant for India, where pneumonia is a leading
cause of child mortality and AMR is a fast-emerging healthcare crisis.
The innovation has successfully cleared pre-clinical trials and will undergo Phase III clinical trials
before commercialization. With a demonstrated ability to improve treatment compliance and
affordability, the technology holds promise not only for India but also for global markets.
Speaking on the occasion, Sh. Rajesh Kumar Pathak, Secretary, TDB, said, “This project
represents a significant stride in addressing pneumonia and antimicrobial resistance, two pressing
healthcare challenges in India and worldwide. By supporting indigenous innovation like AONEUM-04, TDB is reinforcing India’s capability to deliver affordable, scalable, and globally relevant
healthcare solutions.”
The promoters of Aodh Lifesciences Pvt. Ltd. added, “With TDB’s support, we are poised to
advance AONEUM-04 through final clinical trials and bring a truly patient-centric antibiotic therapy
to market. Our mission is to make effective, safe, and affordable treatments accessible to the
masses while contributing to the global fight against antimicrobial resistance.”
****
NKR/PSM
(Release ID: 2165608)